Advanced Filters
noise

Connective Tissue Diseases Clinical Trials

A listing of Connective Tissue Diseases medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 370 clinical trials

RY_SW01 Cell Injection Therapy in Systemic Sclerosis

Systemic sclerosis (SSc) tends to progress to involve multiple vital organs within 5 years of diagnosis, significantly impacting patient prognosis and survival. Clinical indications suggest that early intervention is more favorable for long-term outcomes in patients. Although guidelines recommend various drugs for symptomatic treatment, there is currently no standard therapy …

18 - 65 years of age All Phase 1/2
C Chadwick Prodromos, M.D.

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell IV Infusion for Systemic Sclerosis

This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Systemic Sclerosis

years of age All Phase 1

Analysis of Dermal Fibroblasts and Immune Cells During Systemic Sclerosis

The pathophysiology of systemic sclerosis (SSc) is still poorly understood and there are no effective treatments for this disease. SSc is a heterogeneous disease with varying severity. The heterogeneity of fibroblast profiles, observed in other fibrosing pathologies, has never been thoroughly explored in the skin of SSc patients. The immune …

18 years of age All Phase N/A
C Chloé STAVRIS, MD

Longitudinal Characterization of Microbial Signature in Systemic Sclerosis Patients

Today, the study of gut microbiota has taken a prominent place in several fields of medical research. Numerous experimental data in humans and animals suggest that an imbalance in the composition of the microbiota could contribute to the pathophysiology of systemic autoimmune diseases such as Systemic Sclerosis (SCS). A future …

18 years of age All Phase N/A
周胜男

CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH

This is a single-center, open-label, non-randomized, single-arm clinical trial. Patients with refractory lupus neritis (SLE-LN), systemic sclerosis (SSc), and primary Sjogren syndrome combined with pulmonary artery hypertension (pSS-PAH) receive CD19-BCMA CAR T cell therapy. The primary objective is to prospectively assess the safety of CD19-BCMA CAR T cell therapy in …

10 - 65 years of age All Phase 1/2
X Xiaojing Zhang, MD

Blinatumomab in Refractory Active Childhood Systemic Lupus Erythematosus

The goal of this clinical trial is to learn if blinatumomab works to treat refractory or active systemic lupus erythematosus (SLE) in children and adults. It will also learn about the safety of blinatumomab. The main questions it aims to answer are: Does blinatumomab improve symptoms and disease activity in …

5 years of age All Phase 1

Platelet-Rich Plasma Injections From Cord Blood + Penile Traction vs. Penile Traction Alone in Patients With Peyronie's Disease. Open-label, Single-center Randomized Study

The goal of this clinical trial is to learn if Platelet-Rich Plasma Injections from Cord Blood (CB-PRP) is useful in Peyronie disease. The primary goal is evaluation of patient satisfaction at 1 and 3 months after treatment completion using the PDQ Questionnaire Secondary Objectives are: Measurement of penile curvature measured …

18 - 75 years of age Male Phase N/A

A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases

This study aims to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of OL-CD19-GDT in relapsed/refractory autoimmune diseases.

18 - 65 years of age All Phase 1
Q Qiubai Li, Professor

The Clinical Study on the Treatment of SSc With UTAA91 Injection.

This clinical trial is designed as a single-arm, open-label, single-center investigator-initiated early-phase study, with the primary objective of evaluating the safety of UTAA91 injection in subjects with refractory moderate-to-severe active systemic sclerosis.

18 years of age All Phase 0
P Paul DECKER, MD

Evaluation of Muscle Involvement in Systemic Sclerosis

Muscle involvement is poorly described in patients with systemic sclerosis (SSc) . The prevalence of muscle damage is evaluated at 5-95 % of SSc patients, particularly due to variable definitions depending on the series in the scientific litterature. Muscle clinicobiological and histological presentation an response to immunosuppressive treatments are highly …

18 years of age All Phase N/A

Simplify language using AI